Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

Autor: Jones, Nick K, Rivett, Lucy, Seaman, Shaun, Samworth, Richard J, Warne, Ben, Workman, Chris, Ferris, Mark, Wright, Jo, Quinnell, Natalie, Shaw, Ashley, Cambridge COVID-19 Collaboration, Goodfellow, Ian G, Lehner, Paul J, Howes, Rob, Wright, Giles, Matheson, Nicholas J, Weekes, Michael P, Amory, Amy, Baker, Stephen, Bateman, Emma, Begum, Aklima, Begum, Moushima, Bradley, John, Brennan, Michael, Burn, Helen, Crofts, Caroline, Chaudhry, Afzal, Chaudhry, Yasmin, Cooper, Daniel J, Dawson, Sharon, Dougan, Gordon, Feather, Renny, Free, Louise, Friel, Katie, Gildea, Claire, Georgana, Iliana, Grimwade, Lizz, Gupta, Ravi, Hall, Susan, Hannan, Sophie, Hayes, James, Hosaja, Aleksandra, Hosmillo, Myra, Izuagbe, Rhys, Jahun, Aminu, James, Lidia, Jardin, Jill, Kingston, Nathalie, Lear, Sara, Lyons, Paul A, Maxwell, Patrick H, Mott, Sue, Mugavin, Sarah, Mwiya, Joyce, Peacock, Sharon, Nallattil, Ravi Prakash, Oloyede, Kazeem, Ouwehand, Willem H, Page, Elle, Perez, Marina, Raine, Tim, Routledge, Matthew, Saunders, Caroline, Smith, Kenneth GC, Sparkes, Dominic, Stafford, Maria, Summers, Charlotte, Tatsi, Despiona, Thaventhiran, James ED, Thomas Johnson, Sharon, Török, M Estée, Toshner, Mark, Turner, Lesley, Wall, Kate, Watson, Karis

The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce96e832bfd6c79ac2ffcb2950ab793f